Morgan Stanley raised the firm’s price target on Novartis (NVS) to CHF 108 from CHF 105 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Video: Merger Monday with deals announced in biotechnology and banking
- Avidity acquisition has positive read for Dyne Therapeutics, says Morgan Stanley
- Dyne Therapeutics up 37% after Avidity gets bought
- Avidity Biosciences downgraded to Neutral from Buy at Roth Capital